Analginum Ultra

General characteristics. Structure:

Active ingredient: 0,5 g of metamizole sodium in 1 tablet.

Excipients: potato starch, cellulose microcrystallic, silicon dioxide colloid (aerosil), gipromelloz (gidroksipropilmetiltselyulloz), кросповидон, magnesium stearate, talc; cover: Опадрай II (polyvinyl alcohol, macrogoal, talc, titanium dioxide, pigments (aluminum oxides).

Possesses antiinflammatory, analgeziruyushchy, febrifugal action.

Pharmacological properties:

Pharmacodynamics. Analginum not selectively blocks cyclooxygenase and reduces formation of prostaglandins from arachidonic acid, interferes with carrying out painful extra-and proprioceptive impulses. Analginum Ultra has the subtle antiinflammatory effect causing small influence on a water salt metabolism (a delay of sodium and water) and mucous a GIT.

Has spasmolytic effect on smooth muscles of uric and bilious ways. Action develops in 20-40 minutes after intake.

Pharmacokinetics. It is well and quickly soaked up in a GIT that provides bystry development of clinical effect. At reception in therapeutic doses gets into maternal milk. The maximum concentration in plasma is reached in 1-1,5 h after intake.

In a wall of intestines it is hydrolyzed with formation of an active metabolite, 4-methyl-aminoantipyrine which is in turn metabolized in 4-formyl-amino-antipyrine and other metabolites. Level of linkng of an active metabolite with proteins makes 50-60%.

Ekskrektion of metabolites passes through kidneys. Besides, metabolites are allocated with breast milk.

Indications to use:

Pain syndrome of weak and moderate expressiveness: headache of various etiology, neuralgia, mialgiya, arthralgia, injuries, radiculitis, miositis, альгодисменорея. Analginum Ultra is applied at pains of a visceral origin (at renal, hepatic, intestinal colic) in a combination with antispasmodics. For reduction of pains after surgical and diagnostic interventions. A feverish syndrome against the background of infectious and inflammatory diseases.

Route of administration and doses:

Inside, after food, the adult appoint 500 mg 2-3 times a day, the maximum single dose – 1000 mg, daily – 3000 mg.

Reception duration without consultation with the doctor no more than 5 days as anesthetic and no more than 3 days as febrifugal.

Features of use:

At treatment of the patients receiving cytostatic HP, reception of Analginum Ultra it has to be carried out only under observation of the doctor. Patients with atopic bronchial asthma and pollinoses have an increased risk of development of allergic reactions.

Against the background of reception of Analginum Ultra development of an agranulocytosis in this connection at identification of unmotivated rise in temperature, a fever, pharyngalgias, the complicated swallowing, stomatitis, and also at development of the phenomena of a vaginitis or proctitis immediate drug withdrawal is necessary is possible.

At prolonged use it is necessary to control a pattern of peripheral blood. Use for removal of acute abdominal pains is inadmissible (before clarification of the reason).

Side effects:

From an urinary system: a renal failure, an oliguria, an anury, a proteinuria, intersticial nephrite, coloring of urine in red color.

Allergic reactions: a small tortoiseshell (including on a conjunctiva and mucous membranes of a nasopharynx), a Quincke's disease, in rare instances - a malignant exudative erythema (Stephens-Johnson's syndrome), a toxic epidermal necrolysis (Lyell's disease), a bronkhospastichesky syndrome, an acute anaphylaxis.

From bodies of a hemopoiesis: agranulocytosis, leukopenia, thrombocytopenia. Other: decrease in the ABP.

Interaction with other medicines:

At co-administration of cyclosporine concentration of the last in blood decreases. Co-administration with other non-narcotic analgesics, tricyclic antidepressants, contraceptive hormonal and Allopyrinolum can lead medicines to toxicity strengthening.

Sedative and anxiolytic HP (tranquilizers) strengthen analgeziruyushchy effect of metamizole sodium.

Metamizole sodium strengthens effects of alcohol; simultaneous use with Chlorpromazinum or fenotiaziny can lead to development of the expressed hypothermia. X-ray contrast medicines, colloid blood substitutes and penicillin should not be applied during treatment by metamizole sodium.

At co-administration of cyclosporine concentration of the last in blood decreases.

Metamizole sodium, forcing out peroral hypoglycemic drugs, indirect anticoagulants, corticosteroids and indometacin from communication with protein, increasing their activity.

Phenylbutazone, barbiturates and other inductors of a microsomal oxidation of a liver at co-administration reduce efficiency of metamizole sodium. Effect strengthen codeine, histamine H2 blockers and пропанолол.

Contraindications:

Hypersensitivity to pyrazyl ketone derivatives, hemopoiesis oppression (an agranulocytosis, a neutropenia), a liver and/or renal failure, the hereditary hemolitic anemia connected with deficit glyukozo-6-fosfatdegidrogenazy and other types of anemia, asthma induitsirovanny reception of acetylsalicylic acid, salicylates and other non-steroidal anti-inflammatory drugs, a leukopenia, pregnancy (especially in the I trimester and in the last 6 weeks), the lactation period, children's age up to 15 years.

With caution it is necessary to take drug at diseases of kidneys (pyelonephritis, a glomerulonephritis – including in the anamnesis), at moderately expressed disturbances of a liver and kidneys, bronchial asthma, predisposition to development of arterial hypotension, long alcohol intake.

Overdose:

Symptoms: nausea, vomiting, gastralgia, oliguria, hypothermia, lowerings of arterial pressure, tachycardia, short wind, sonitus, drowsiness, nonsense, consciousness disturbance, acute agranulocytosis, hemorrhagic syndrome, acute renal and/or liver failure, spasms, paralysis of respiratory muscles.

Treatment: a gastric lavage, salt laxatives, absorbent carbon, carrying out an artificial diuresis, a hemodialysis, at development of a convulsive syndrome - intravenous administration of diazepam and high-speed barbiturates.

Storage conditions:

List B. In the dry place protected from light at a temperature not above 25 °C. A period of validity - 5 years. Not to use after the date specified on packaging.

Issue conditions:

Without recipe

Packaging:

On 5, 10 or 20 tablets in a blister strip packaging from a film of the polyvinyl chloride and printing aluminum foil varnished. On 1, 2, 5, 10 or 14 blister strip packagings with the application instruction place in a pack from a cardboard.